Total Payments
$85,273
2024 Payments
$23,430
Companies
15
Transactions
95
Medicare Patients
61
Medicare Billing
$13,163
Payment Breakdown by Category
Consulting$43,883 (51.5%)
Research$40,907 (48.0%)
Food & Beverage$482.85 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,883 | 58 | 51.5% |
| Unspecified | $40,907 | 23 | 48.0% |
| Food and Beverage | $482.85 | 14 | 0.6% |
Payments by Type
General
$44,366
72 transactions
Research
$40,907
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $26,703 | 37 | $0 (2024) |
| Eli Lilly and Company | $11,404 | 6 | $0 (2022) |
| UCB Biosciences Inc. | $10,270 | 2 | $0 (2023) |
| AstraZeneca AB | $9,904 | 12 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $7,705 | 3 | $0 (2024) |
| SANOFI US SERVICES INC. | $5,661 | 6 | $0 (2021) |
| Celgene Corporation | $4,875 | 3 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $4,153 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,042 | 4 | $0 (2020) |
| BIOVERATIV THERAPEUTICS INC. | $1,554 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,430 | 27 | AstraZeneca UK Limited ($19,494) |
| 2023 | $8,938 | 6 | UCB Biosciences Inc. ($3,612) |
| 2022 | $7,525 | 3 | UCB Biosciences Inc. ($6,658) |
| 2021 | $13,775 | 18 | AstraZeneca AB ($6,100) |
| 2020 | $7,036 | 11 | AstraZeneca Pharmaceuticals LP ($2,000) |
| 2019 | $12,560 | 13 | SANOFI US SERVICES INC. ($3,911) |
| 2018 | $11,851 | 11 | Eli Lilly and Company ($7,500) |
| 2017 | $158.28 | 6 | E.R. Squibb & Sons, L.L.C. ($144.34) |
All Payment Transactions
95 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 12/24/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 10/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 10/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 10/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 09/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 09/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 09/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 08/29/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $3,230.00 | Research |
| Study: A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | ||||||
| 08/29/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 08/29/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 08/20/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/29/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 07/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 07/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 05/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 05/30/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 03/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,134.00 | General |
| 02/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 02/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 02/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| 02/15/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $680.00 | Research |
| Study: A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | UCB Biosciences Inc. | $10,270 | 2 |
| A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3361237 IN HEALTHY SUBJECTS | Eli Lilly and Company | $3,804 | 2 |
| A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED STUDY OF LY3316531 IN HEALTHY SUBJECTS AND AN OPEN-LABEL, SINGLE-DOSE STUDY IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $3,750 | 1 |
| A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | Novartis Pharmaceuticals Corporation | $3,230 | 1 |
| A first-in-human, randomized, participant- and investigator-blinded, placebo-controlled, two-part, single ascending intravenous dose study, to assess the safety, tolerability, and pharmacokinetics of VHB937 in healthy non-Japanese and Japanese adults | Novartis Pharmaceuticals Corporation | $2,975 | 1 |
| A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | Regeneron Pharmaceuticals, Inc. | $2,338 | 3 |
| A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects with Moderate to Severe Plaque-type Psoriasis (CC-90005-CP-001) | Celgene Corporation | $2,250 | 1 |
| A SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LY3375880 IN HEALTHY SUBJECTS | Eli Lilly and Company | $2,250 | 1 |
| A MULTI PART STUDY OF ZPL389 A HISTAMINE H4 RECEPTOR ANTAGONIST CONSISTING OF RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY PARTS TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS IN HEALTHY JAPANESE AND NON JAPANESE VOLUNTEERS AND AN OPEN LABEL FOOD EFFECTS STUDY PART IN HEALTHY VOLUNTEERS NONJAPANESE | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| CC-90005-CP-001 - A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subj | Celgene Corporation | $1,500 | 1 |
| Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Single Ascending Dose Administration to Healthy Male Subjects with Elevated LDL-C Levels | AstraZeneca AB | $1,500 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Volunteers | Regeneron Pharmaceuticals, Inc. | $1,136 | 2 |
| Maximum Tolerated Dose - Japan (CC-92252-CP-002) (BMS Study Number: IM041-P02) (CC-92252-CP-002) | Celgene Corporation | $1,125 | 1 |
| A Phase I, randomized, single-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of AZD2693 following single-ascending-dose administration to overweight but otherwise healthy male subjects and healthy female subjects of non-childbearing potential. | AstraZeneca UK Limited | $1,000 | 1 |
| A PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, SINGLE-ASCENDING DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS, AND MULTIPLE-DOSE STUDY OF LY3844583 IN HEALTHY PARTICIPANTS AND PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $850.00 | 1 |
| SINGLE-DOSE, DOSE-ESCALATION STUDY WITH LY3303560 TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN HEALTHY SUBJECTS AND PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | Eli Lilly and Company | $750.00 | 1 |
| A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | Regeneron Pharmaceuticals, Inc. | $680.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 18 | 55 | $9,350 | $4,565 |
| 2021 | 2 | 32 | 84 | $14,382 | $7,480 |
| 2020 | 1 | 11 | 12 | $2,112 | $1,117 |
Total Patients
61
Total Services
151
Medicare Billing
$13,163
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 55 | $9,350 | $4,565 | 48.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 67 | $11,390 | $5,920 | 52.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 16 | 17 | $2,992 | $1,560 | 52.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 11 | 12 | $2,112 | $1,117 | 52.9% |
About Dr. Andrew Williams, M.D
Dr. Andrew Williams, M.D is a Internal Medicine healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2014. The National Provider Identifier (NPI) number assigned to this provider is 1245641869.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Williams, M.D has received a total of $85,273 in payments from pharmaceutical and medical device companies, with $23,430 received in 2024. These payments were reported across 95 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($43,883).
As a Medicare-enrolled provider, Williams has provided services to 61 Medicare beneficiaries, totaling 151 services with total Medicare billing of $13,163. Data is available for 3 years (2020–2022), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Pasadena, CA
- Active Since 05/16/2014
- Last Updated 01/15/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1245641869
Products in Payments
- BIVV020 (Drug) $3,911
- CC-90005 (Drug) $3,750
- ZPL389A (Drug) $1,500
- CC-92252 (Drug) $1,125
- ELIQUIS (Drug) $279.75
- Aimovig (Biological) $117.92
- LOKELMA (Drug) $42.48
- XARELTO (Drug) $26.03
- CAMZYOS (Drug) $16.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Pasadena
Dr. Yuan Yuan, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $523,801
Internal Medicine $523,801
Christopher Dagher, M.d, M.D
Internal Medicine — Payments: $103,615
Internal Medicine $103,615
Peter Haddad, M.d, M.D
Internal Medicine — Payments: $87,600
Internal Medicine $87,600
Joseph Dellinger, Md, MD
Internal Medicine — Payments: $77,175
Internal Medicine $77,175
Dr. Helen Moon, M.d, M.D
Internal Medicine — Payments: $61,882
Internal Medicine $61,882
John Debeixedon, M D, M D
Internal Medicine — Payments: $50,465
Internal Medicine $50,465